JP2023504149A - Cd300c抗原またはその受容体に特異的に結合するキメラ抗原受容体 - Google Patents
Cd300c抗原またはその受容体に特異的に結合するキメラ抗原受容体 Download PDFInfo
- Publication number
- JP2023504149A JP2023504149A JP2022532160A JP2022532160A JP2023504149A JP 2023504149 A JP2023504149 A JP 2023504149A JP 2022532160 A JP2022532160 A JP 2022532160A JP 2022532160 A JP2022532160 A JP 2022532160A JP 2023504149 A JP2023504149 A JP 2023504149A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- receptor
- cd300c
- chimeric antigen
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 title claims abstract description 63
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 title claims abstract description 63
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 58
- 108020003175 receptors Proteins 0.000 title claims abstract description 53
- 102000005962 receptors Human genes 0.000 title claims abstract description 53
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 66
- 201000011510 cancer Diseases 0.000 claims abstract description 57
- 210000002865 immune cell Anatomy 0.000 claims abstract description 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 11
- 206010027476 Metastases Diseases 0.000 claims abstract description 4
- 230000009401 metastasis Effects 0.000 claims abstract description 4
- 230000005907 cancer growth Effects 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229940041181 antineoplastic drug Drugs 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 108010083359 Antigen Receptors Proteins 0.000 claims description 2
- 102000006306 Antigen Receptors Human genes 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010059866 Drug resistance Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000005087 mononuclear cell Anatomy 0.000 claims description 2
- 201000005443 oral cavity cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 60
- 230000000694 effects Effects 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 239000002955 immunomodulating agent Substances 0.000 abstract description 2
- 230000001629 suppression Effects 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000001093 anti-cancer Effects 0.000 description 12
- 230000027455 binding Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710083129 50S ribosomal protein L10, chloroplastic Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003006 anti-agglomeration agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002584 immunological anticancer agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
実施例1:CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体発現ベクターの製造
CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体を製造するために、pLVX-Puroベクター(Addgene)に、合成された蛋白質が細胞膜を通過して正確な位置に移動するようにする配列番号2のアミノ酸配列を含むCD8αシグナルペプチド(CD8αsignal peptide、DNA配列は配列番号1)、CD300c抗原またはその受容体に特異的に結合する各配列番号4、6、8、10、12のアミノ酸配列を含むCK1、CL6、CL7、CL10、SL18それぞれの単鎖可変領域フラグメント(anti-CD300c single chain variable fragment;aCD300c scFv、DNA配列はそれぞれ配列番号3、5、7、9、11)または配列番号14のアミノ酸配列を含むCD300c ECD(extracellular domain)抗原(DNA配列は配列番号13)、配列番号16のアミノ酸配列を含むGSリンカー(DNA配列は配列番号15)、そして膜貫通ドメイン(transmembrane domain)として配列番号18のアミノ酸配列を含むCD8ヒンジ(hinge of cluster of differentiation 8、DNA配列は配列番号17)、配列番号20のアミノ酸配列を含むCD28膜貫通ドメイン(CD28 transmembrane domain、DNA配列は配列番号19)、そして大食細胞活性化信号伝達のための細胞質内ドメイン(intracytoplasmic domain)として配列番号22のアミノ酸配列を含むCD28細胞内ドメイン(CD28 intracellular domain、DNA配列は配列番号21)、および配列番号24のアミノ酸配列を含むCD3ζ細胞内ドメイン(CD3ζintracellular domain、DNA配列は配列番号23)を順に挿入して、CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体発現ベクター(pLVX-Puro/aCD300c scFvまたはpLVX-Puro/CD300c ECD-CAR)を製造した。製造した各ベクターの遺伝子および蛋白質配列の組み合わせは表1に表した。そして遺伝子の配列の模式図は図1に示し、製作されたベクターマップの例示は図2に示した。
CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体発現用組換えレンチウイルスの製造に必要なHEK293T細胞株(ATCC)を、次のように準備した。細胞の培養に使った完全培地は、新鮮なDMEM培地(Gibco)に熱処理したFBS(fetal bovine serum)を10%の濃度となるように添加し、1XのPenicillin-Streptomycin(Gibco)を添加した後に、上下に転倒させて均一に混合した後に37℃で予熱して使った。そしてHEK293T細胞株は冷凍保管された細胞stockを使用前に迅速に37℃恒温水槽に転移して、2~3分の間急速解凍した後に、30mLの完全培地に接種し、37℃、5%CO2培養器で培養した。そして細胞飽和度が80%以上となった時、継代培養しながら維持した。レンチウイルスの形質感染(transfection)のためには、HEK293T細胞株を1-2 X 106cellsの濃度で10mLの完全培地に接種し、16時間の間培養した後に、レンチウイルスの形質感染を実施した。
CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体を発現するJurkat細胞を製造するために、実施例2と同一の方法で製造された組換えレンチウイルスをJurkat細胞株に形質感染させた。より詳しくは、0.1~10MOIの組換えレンチウイルスを8μg/mLのpolybrene(Merk)が添加された完全培地に接種し、上下に転倒させて均一に混合した。そして混合物を6-ウェルプレートに準備されたJurkat細胞株に1mLずつ添加した後に、1,800rmpで45~90分の間遠心分離し、37℃、5%CO2培養器で24時間の間培養した。そして24時間後に、5X105cells/mLの濃度で継代培養した。
CD300cが多様ながん細胞で発現しているかを評価するために、多様なヒト由来固形がん細胞株を培養してmRNAおよび蛋白質水準でCD300cの発現を評価した。より詳しくは、ヒト肺がん細胞株であるA549、ヒト乳ガン細胞株であるMDA-MB-231、マウス大腸がん細胞株であるCT26を培養し、それぞれの細胞を4%ホルムアルデヒドで固定させた後に、5%Normal goat serumを利用してブロッキングした。そして1μgの抗-CD300c抗体を処理し反応させた後に、FITC-labeled抗-rabbit IgG抗体を利用して染色した。そして蛍光標識された細胞をフローサイトメーター(FACS)を利用して確認した。
CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体を発現するJurkat細胞の抗がん効果を確認するために、A549細胞株を利用してがん細胞死滅効果を確認した。より詳しくは、A549細胞株を96-ウェルプレートに1X105cells/mLの濃度で接種した。そして実施例3に記載された方法と同一の方法で製造されたCD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体を発現するJurkat細胞をがん細胞に20:1の濃度となるように処理し共培養した。対照群としてレンチウイルスで形質感染されていないJurkat細胞を使った。24時間の間共培養した後に、各ウェルから共培養したJurkat細胞株を除去し、CCK-8(Dojindo)を利用して1時間の間反応させた後に、OD450nmで吸光度を測定してがん細胞の死滅程度を確認した。その結果は図4に示した。
Claims (16)
- CD300c抗原またはその受容体に特異的に結合するキメラ抗原受容体であって、
前記キメラ抗原受容体はCD300c抗原またはその受容体に特異的に結合する抗体、単一ドメイン抗体、単鎖可変領域フラグメント、および抗原からなる群から選択されたいずれか一つ以上を含むことを特徴とする、キメラ抗原受容体。 - 前記キメラ抗原受容体は、配列番号4、6、8、10、12または14で表示されるアミノ酸配列を含むことを特徴とする、請求項1に記載のキメラ抗原受容体。
- 前記キメラ抗原受容体は、シグナルペプチド(signal peptide)、GSリンカー、膜貫通ドメイン(transmembrane domain)、および細胞質内ドメイン(intracytoplasmic domain)を追加で含むことを特徴とする、請求項1に記載のキメラ抗原受容体。
- 前記シグナルペプチドはCD8αシグナルペプチドであることを特徴とする、請求項3に記載のキメラ抗原受容体。
- 前記膜貫通ドメインはCD8ヒンジ(hinge of cluster of differentiation 8)およびCD28膜貫通ドメイン(CD28 transmembrane domain)であることを特徴とする、請求項3に記載のキメラ抗原受容体。
- 前記細胞質内ドメインはCD28細胞内ドメイン(CD28 intracellular domain)およびCD3ζ細胞内ドメイン(CD3ζintracellular domain)であることを特徴とする、請求項3に記載のキメラ抗原受容体。
- 前記キメラ抗原受容体は、CD300c抗原またはCD300c受容体を発現するがんの治療用途で使われることを特徴とする、請求項1に記載のキメラ抗原受容体。
- 請求項1~請求項7のいずれか一項に記載されたキメラ抗原受容体を発現する、組換えベクター。
- 請求項8に記載された組換えベクターで形質転換された、免疫細胞。
- 前記免疫細胞は、単核球、大食細胞、T細胞、ナチュラルキラー細胞(Natural killer cell;NK cell)および樹枝状細胞からなる群から選択されたいずれか一つ以上であることを特徴とする、請求項9に記載の免疫細胞。
- 請求項9に記載された免疫細胞を有効性分として含む、CD300c抗原またはCD300c受容体を発現するがんの予防または治療用薬学的組成物。
- 前記がんは、大腸がん、直腸がん、結腸がん、甲状腺がん、口腔がん、咽頭がん、喉頭がん、子宮頸がん、脳がん、肺がん、卵巣がん、膀胱がん、腎臓がん、肝臓がん、すい臓がん、前立腺がん、皮膚がん、舌がん、乳ガン、子宮がん、胃がん、骨がんおよび血液がんからなる群から選択されたいずれか一つ以上であることを特徴とする、請求項11に記載の薬学的組成物。
- 前記薬学的組成物は他の抗がん剤を追加で含むことを特徴とする、請求項11に記載の薬学的組成物。
- 前記薬学的組成物はがんの増殖、生存、転移、再発または抗がん剤耐性を抑制することを特徴とする、請求項11に記載の薬学的組成物。
- 請求項9に記載された免疫細胞を有効性分として含む組成物を個体に投与する段階を含む、がんの予防または治療方法。
- 請求項9に記載された免疫細胞を有効性分として含む組成物のがん予防または治療用途。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0155027 | 2019-11-28 | ||
KR20190155027 | 2019-11-28 | ||
KR10-2020-0162200 | 2020-11-27 | ||
KR1020200162200A KR20210066743A (ko) | 2019-11-28 | 2020-11-27 | CD300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |
PCT/KR2020/017230 WO2021107726A1 (ko) | 2019-11-28 | 2020-11-30 | Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023504149A true JP2023504149A (ja) | 2023-02-01 |
Family
ID=76128743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022532160A Pending JP2023504149A (ja) | 2019-11-28 | 2020-11-30 | Cd300c抗原またはその受容体に特異的に結合するキメラ抗原受容体 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4067379A4 (ja) |
JP (1) | JP2023504149A (ja) |
CN (1) | CN115038719A (ja) |
AU (1) | AU2020394279A1 (ja) |
CA (1) | CA3159889A1 (ja) |
WO (1) | WO2021107726A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022250433A1 (ko) * | 2021-05-24 | 2022-12-01 | 주식회사 센트릭스바이오 | Cd300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
KR20160016725A (ko) | 2014-08-05 | 2016-02-15 | 주식회사 유영제약 | 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포 |
US20180334490A1 (en) * | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
-
2020
- 2020-11-30 CA CA3159889A patent/CA3159889A1/en active Pending
- 2020-11-30 AU AU2020394279A patent/AU2020394279A1/en active Pending
- 2020-11-30 EP EP20893965.2A patent/EP4067379A4/en active Pending
- 2020-11-30 CN CN202080094897.2A patent/CN115038719A/zh active Pending
- 2020-11-30 JP JP2022532160A patent/JP2023504149A/ja active Pending
- 2020-11-30 WO PCT/KR2020/017230 patent/WO2021107726A1/ko unknown
Also Published As
Publication number | Publication date |
---|---|
EP4067379A1 (en) | 2022-10-05 |
EP4067379A4 (en) | 2023-12-27 |
AU2020394279A1 (en) | 2022-06-16 |
WO2021107726A1 (ko) | 2021-06-03 |
CN115038719A (zh) | 2022-09-09 |
CA3159889A1 (en) | 2021-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA126897C2 (uk) | Антитіла проти dr5 і способи їх застосування | |
US11427645B2 (en) | 5T4-targeting agents and methods | |
CA2987607A1 (en) | Tigit-binding agents and uses thereof | |
BR112020000228A2 (pt) | anticorpos que modulam uma atividade biológica expressa por célula | |
JP2017530724A (ja) | 多様な多重抗原のターゲティングのための汎用的キメラ抗原受容体を発現する免疫細胞および該免疫細胞の製造方法ならびに該免疫細胞の、癌、感染症および自己免疫疾患の治療のための使用 | |
AU2019279311B2 (en) | Pharmaceutical composition for preventing or treating cancer, containing CD300C expression inhibitor or activity inhibitor | |
JP2020525505A (ja) | 癌治療のための抗fam19a5抗体の用途 | |
AU2015300006B2 (en) | Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody | |
WO2020015703A1 (zh) | 喹啉衍生物与抗体的药物组合 | |
AU2017271606A1 (en) | FLT3-specific chimeric antigen receptors and methods using same | |
CN114616337A (zh) | 嵌合CD3融合蛋白与基于anti-CD3的双特异性T细胞激活元件的联合表达 | |
JP2023504149A (ja) | Cd300c抗原またはその受容体に特異的に結合するキメラ抗原受容体 | |
JP7033601B2 (ja) | 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞 | |
WO2018047917A1 (ja) | Hmgタンパク質と抗cd4抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果 | |
CN115297881A (zh) | 包含含有il-2蛋白和cd80蛋白的融合蛋白和抗癌药物的用于治疗癌症的药物组合物 | |
US20230357385A1 (en) | Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody | |
EP3950713A1 (en) | Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof | |
KR20210060355A (ko) | 항-CD300c 단클론 항체를 포함하는 암 예방 또는 치료용 조성물 | |
WO2019149172A1 (zh) | Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用 | |
KR20210066743A (ko) | CD300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체 | |
BR112021006254A2 (pt) | composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos | |
JP2023503567A (ja) | 抗-cd300c単クローン抗体を含むがん予防または治療用組成物 | |
WO2012133914A1 (ja) | Ranklアンタゴニストを含む癌免疫増強剤 | |
RU2810002C2 (ru) | Однодоменные антитела, направленные против внутриклеточных антигенов | |
WO2024097652A2 (en) | Anti-kras t cell receptors and engineered cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240305 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240507 |